Compare TR & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TR | WGS |
|---|---|---|
| Founded | 1896 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Retail: Computer Software & Peripheral Equipment |
| Sector | Consumer Staples | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.7B |
| IPO Year | 1994 | 2020 |
| Metric | TR | WGS |
|---|---|---|
| Price | $38.36 | $83.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $120.71 |
| AVG Volume (30 Days) | 123.4K | ★ 439.7K |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.85% | N/A |
| EPS Growth | 12.30 | ★ 62.37 |
| EPS | ★ 0.41 | N/A |
| Revenue | N/A | ★ $427,539,000.00 |
| Revenue This Year | N/A | $29.98 |
| Revenue Next Year | N/A | $25.92 |
| P/E Ratio | $93.07 | ★ N/A |
| Revenue Growth | N/A | ★ 39.97 |
| 52 Week Low | $34.44 | $32.21 |
| 52 Week High | $45.06 | $170.87 |
| Indicator | TR | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 33.92 | 58.45 |
| Support Level | $37.02 | $81.37 |
| Resistance Level | $38.51 | $94.82 |
| Average True Range (ATR) | 0.81 | 4.17 |
| MACD | -0.40 | -0.74 |
| Stochastic Oscillator | 9.09 | 39.84 |
Tootsie Roll Industries Inc manufactures and sells confectionery products. Notable varieties include Tootsie Roll and Tootsie Pops, Charms, Blow-Pops, Dots, Junior Mints, Sugar Daddy and Sugar Babies, Andes, Dubble Bubble, Razzles among others. The company sells its products to wholesale distributors and directly to retail stores. Geographically, it generates a majority of its revenue from the United States and rest from Canada, Mexico and other regions.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.